PTI - Proteostasis Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
1.0450
-0.0150 (-1.42%)
As of 3:40PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close1.0600
Open1.0700
Bid1.0400 x 1000
Ask1.0500 x 3100
Day's Range1.0300 - 1.0700
52 Week Range0.9100 - 10.3800
Volume250,415
Avg. Volume2,173,414
Market Cap53.399M
Beta (3Y Monthly)-1.82
PE Ratio (TTM)N/A
EPS (TTM)-1.5300
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.60
Trade prices are not sourced from all markets
  • How Proteostasis Therapeutics, Inc. (NASDAQ:PTI) Could Add Value To Your Portfolio
    Simply Wall St.6 days ago

    How Proteostasis Therapeutics, Inc. (NASDAQ:PTI) Could Add Value To Your Portfolio

    I've been keeping an eye on Proteostasis Therapeutics, Inc. (NASDAQ:PTI) because I'm attracted to its fundamentals...

  • PR Newswire16 days ago

    Proteostasis Therapeutics Receives Orphan Drug Designation in the EU for PTI-428 for the Treatment of Cystic Fibrosis

    BOSTON, June 4, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today announced that the European Commission (EC) has granted orphan drug designation (ODD) to PTI-428 for the treatment of cystic fibrosis. PTI-428 is the Company's proprietary cystic fibrosis transmembrane conductance regulator (CFTR) amplifier that is currently in clinical development.

  • PR Newswire17 days ago

    Proteostasis Therapeutics Announces Presentations and Hosts Educational Symposium at the 42nd European Cystic Fibrosis Conference

    BOSTON , June 3, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to ...

  • Vertex Selects Triple Combo Regimen for Regulatory Submission
    Zacks20 days ago

    Vertex Selects Triple Combo Regimen for Regulatory Submission

    Vertex (VRTX) choses VX-445 triple combination regimen for global regulatory submissions to seek approval for the regimen as a treatment for cystic fibrosis based on 24-week phase III study data.

  • PR Newswirelast month

    Proteostasis Therapeutics to Present at the 2019 RBC Capital Markets Global Healthcare Conference

    BOSTON, May 15, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today announced that Proteostasis management will present at the 2019 RBC Capital Markets Global Healthcare Conference on Wednesday, May 22, 2019 at 9:00 a.m. ET at the InterContinental New York Barclay. A live audio webcast of the RBC Capital Markets Global Healthcare Conference presentation will be available on the Investor Events page in the Investors & Media section of the Company's website, www.proteostasis.com. Proteostasis Therapeutics, Inc. is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis and other diseases caused by dysfunctional protein processing.

  • PR Newswirelast month

    Proteostasis Therapeutics Appoints Dr. Badrul Chowdhury, Former FDA Director of Pulmonology, Allergy, and Rheumatology, to Board of Directors

    BOSTON, May 13, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today announced that Badrul A. Chowdhury, M.D., Ph.D., has been appointed to the Company's Board of Directors. Dr. Chowdhury is Senior Vice President and Chief Physician-Scientist, Respiratory Inflammation and Autoimmunity (RIA) Late Stage, R&D Biopharmaceuticals, at AstraZeneca.  He was previously Director of the Division of Pulmonary, Allergy, and Rheumatology Products at the U.S. Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER).

  • Proteostasis Therapeutics (PTI) Reports Q1 Loss, Tops Revenue Estimates
    Zackslast month

    Proteostasis Therapeutics (PTI) Reports Q1 Loss, Tops Revenue Estimates

    Proteostasis (PTI) delivered earnings and revenue surprises of 34.88% and 525.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Presslast month

    Proteostasis: 1Q Earnings Snapshot

    On a per-share basis, the Boston-based company said it had a loss of 28 cents. The biopharmaceutical company posted revenue of $5 million in the period. In the final minutes of trading on Wednesday, the ...

  • PR Newswirelast month

    Proteostasis Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update

    BOSTON, May 8, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today announced financial results for the first quarter ended March 31, 2019 and provided a corporate update. "During the first quarter, we reported a compelling safety and efficacy data set from our 14-day studies, which led us to prioritize the clinical development of our proprietary combination cystic fibrosis transmembrane conductance regulator (CFTR) modulators," said Meenu Chhabra, President and Chief Executive Officer of Proteostasis Therapeutics.

  • Proteostasis (PTI) to Post Q1 Earnings: What's in Store?
    Zackslast month

    Proteostasis (PTI) to Post Q1 Earnings: What's in Store?

    During Proteostasis' (PTI) Q1 earnings call, investor focus will be on its update pertaining to the progress of studies, evaluating its triple combination regimes for cystic fibrosis.

  • Market Sentiment Around Loss-Making Proteostasis Therapeutics, Inc. (NASDAQ:PTI)
    Simply Wall St.2 months ago

    Market Sentiment Around Loss-Making Proteostasis Therapeutics, Inc. (NASDAQ:PTI)

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Proteostasis Therapeutics, Inc.'s (NASDAQ:PTI): Proteostasis Therapeutics, Inc., a clinical sta...

  • Analysts Estimate Proteostasis Therapeutics (PTI) to Report a Decline in Earnings: What to Look Out for
    Zacks2 months ago

    Analysts Estimate Proteostasis Therapeutics (PTI) to Report a Decline in Earnings: What to Look Out for

    Proteostasis (PTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Implied Volatility Surging for Proteostasis Therapeutics (PTI) Stock Options
    Zacks2 months ago

    Implied Volatility Surging for Proteostasis Therapeutics (PTI) Stock Options

    Investors need to pay close attention to Proteostasis Therapeutics (PTI) stock based on the movements in the options market lately.

  • Proteostasis Plunges on Weak Data From Cystic Fibrosis Study
    Zacks3 months ago

    Proteostasis Plunges on Weak Data From Cystic Fibrosis Study

    Proteostasis (PTI) announces data from a phase I study evaluating its triplet combination in cystic fibrosis. Although data were promising, it was weaker than rival Vertex's triplet combinations.

  • Some Proteostasis Therapeutics (NASDAQ:PTI) Shareholders Have Taken A Painful 86% Share Price Drop
    Simply Wall St.3 months ago

    Some Proteostasis Therapeutics (NASDAQ:PTI) Shareholders Have Taken A Painful 86% Share Price Drop

    Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! As an investor, mistakes are inevitable. But really big lossesRead More...

  • Benzinga3 months ago

    The Daily Biotech Pulse: Japanese Cheer For AbbVie, Myokardia Offering, CytomX CFO Departs

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 25) Axsome Therapeutics Inc (NASDAQ: AXSM ) Catalyst Pharmaceuticals ...

  • Why Vertex's Grip On This Huge Sales Opportunity Now Looks Unbreakable
    Investor's Business Daily3 months ago

    Why Vertex's Grip On This Huge Sales Opportunity Now Looks Unbreakable

    A tiny biotech called Proteostasis won't be able to rival Vertex in cystic fibrosis treatment, analysts said Monday. Proteostasis' triple-medicine missed the bar set by Vertex's treatment.

  • Proteostatis stock plunges on cystic fibrosis triple combo data
    American City Business Journals3 months ago

    Proteostatis stock plunges on cystic fibrosis triple combo data

    What would otherwise be promising data led to a 60 percent stock price slide, as it falls far below both triple combination treatments being developed by the cystic fibrosis market leader, Vertex.

  • MarketWatch3 months ago

    Proteostasis Therapeutics's stock plunges to pace all decliners after results of CF treatment trial disappoint

    Shares of Proteostasis Therapeutics Inc. plunged 58% on heavy volume in morning trade Monday, enough to pace all decliners trading on major U.S. exchanges, after biopharmaceutical company announced results from a phase 1 study of its cystic fibrosis (CF) treatment. Trading volume ballooned to 7.6 million shares, compared with the full-day average of 1.2 million shares. The company said the increase in ppFEV1 at day 14 of a statistically significant 5 percentage points versus baseline was observed in the 600 milligram PTI-801 cohort. Analyst Geoffrey Porges at SVB Leerink said the results CF did not meet the efficacy of Vertex Pharmaceuticals Inc.'s medicines, as that 5% was below the 13%-14% hurdle established by Vertex. Porges believes the results of Proteostasis' trial removes the final "long-shot competitor" to Vertex's CF portfolio. Vertex shares gained 1.0% in morning trade. Proteostasis's stock has lost 66.3% over the past 12 months, while Vertex shares have rallied 13.8% and the S&P 500 has gained 7.8%.

  • PR Newswire3 months ago

    Proteostasis Therapeutics Announces Broad New Dataset from Proprietary Combination and Add-On CFTR Modulator Studies in Cystic Fibrosis Patients

    Greatest ppFEV1 Improvement Shown in High Dose Triplet with Mean Absolute Improvement in ppFEV1 of 8 Percentage Points at 14 Days Compared to Placebo (p All Combinations Studied Were Well-Tolerated, Including ...

  • Benzinga3 months ago

    The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs

    Biotech stocks came under pressure last week despite two FDA approvals coming through. The FDA approved SAGE Therapeutics Inc (NASDAQ: SAGE )'s drug to treat postpartum depression and Jazz Pharmaceuticals ...

  • Vertex's VX-445 Triple Combo Cystic Fibrosis Trials Succeed
    Zacks3 months ago

    Vertex's VX-445 Triple Combo Cystic Fibrosis Trials Succeed

    Vertex's (VRTX) two phase III studies evaluating a triple combination regimen of VX-445 plus tezacaftor and ivacaftor meet the primary endpoint. The company delays filing for U.S. approval.

  • PR Newswire3 months ago

    Proteostasis Therapeutics Appoints David Arkowitz to Board of Directors

    BOSTON, March 7, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today announced that David Arkowitz has been appointed to the Company's Board of Directors. Mr. Arkowitz is the Chief Financial Officer (CFO) and Treasurer of Flexion Therapeutics, a publicly traded, commercial stage biotechnology company. Prior to joining Flexion, Mr. Arkowitz served as Chief Operating Officer and CFO at Visterra, a biotechnology company which was acquired by Otsuka Pharmaceutical Co., where he led the finance, business development, corporate planning and other functions.

  • PR Newswire4 months ago

    Proteostasis Selected to Join European Consortium to Pioneer Personalized Medicine in Cystic Fibrosis

    BOSTON, Feb. 27, 2019 /PRNewswire/ -- Proteostasis Therapeutics, Inc. (PTI), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing, today announced it has been invited to join the HIT-CF Europe, a pan European strategic initiative which seeks to validate a personalized therapy approach for CF patients with extremely rare genetic mutations. HIT-CF is a consortium of researchers, doctors, pharmaceutical companies and patient representatives, which aims to provide better treatment for people with CF.

  • GlobeNewswire4 months ago

    Detailed Research: Economic Perspectives on Novartis AG, Proteostasis Therapeutics, Williams-Sonoma, Magna International, YRC Worldwide, and Delek Logistics Partners — What Drives Growth in Today's Competitive Landscape

    NEW YORK, Feb. 25, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.